BioMarin Pharmaceutical Story Overview

BMRN -- USA Stock  

USD 98.43  0.08  0.08%

Macroaxis does not monitor all media channels or aggregates social signals for BioMarin Pharmaceutical. But even though we do not provide professional-grade financial sentiment analysis on BioMarin Pharmaceutical, we do publish noise-free headlines that can be used to derive useful patterns or even a trading strategy for BioMarin Pharmaceutical. Check also BioMarin Pharmaceutical Hype Analysis, BioMarin Pharmaceutical Correlation and BioMarin Pharmaceutical Performance.
Bona fide gift to Robert Baffi of 2675 shares of BioMarin Pharmaceutical subject to Section 16
Filed transaction by Biomarin Pharmaceutical I officer. Exempt bona fide gift subject to Rule 16b-3

BioMarin Pharmaceutical Inc insider trading alert for gift of common stock by Robert Baffi, EVP Technical Operations, on January 3, 2018. This event was filed by Biomarin Pharmaceutical I with SEC on 2016-03-07. Statement of changes in beneficial ownership - SEC Form 4. Robert Baffi is currently serves as executive vp of technical operations of BioMarin Pharmaceutical

Cash Floor Correlation

Click cells to compare fundamentals   View All Correlations

Story Momentum

This media report from MacroaxisInsider distributed on January 3, 2018 was a factor to the next trading day price decrease.The overall trading delta against the next closing price was 1.91% . The overall trading delta when the story was published against the current closing price is 6.65% .

Similar stores for BioMarin Pharmaceutical

Notable Stocks in Focus 58.com Inc., , BioMarin Pharmaceutical Inc.,news
Global Export Lines Analysts focus on Buy position BioMarin Pharmaceutical Inc. Street Observer Analyst Research Roundup BioMarin Pharmaceutical Inc. , TherapeuticsMD, Inc. Analyst JournalFull coverage
few days ago at http://www.thecoinguild.com 
Stock in Focus Investors Taking a Second Look at BioMarin Pharmaceutical Inc.
news
The Coin GuildMidSouth Bancorp, Inc. Reports Quarterly Dividends and Election of D. Michael Mike Kramer to Board of Directors Business WireFull coverage
over a week ago at http://www.streetobserver.com 
Sale by Jeff Ajer of 1436 shares of BioMarin Pharmaceutical
news
Filed transaction by Biomarin Pharmaceutical I officer. General open market or private sale of non-derivative or derivative security
Stock for High Risk Taking Investors BioMarin Pharmaceutical Inc.news
Wallstreet InvestorplaceFull coverage
over two weeks ago at http://www.nasdaq.com 
3 Biotech Stocks Up in the Past Month on Industry Turnaround
nasdaq News
NasdaqFull coverage
over two weeks ago at http://www.journalfinance.net 
Stocks Views And Recommendations Chicos FAS, Inc. , BioMarin Pharmaceutical Inc. NASDAQBMRN ...
news
Market Breaking Point Full coverage
over three weeks ago at www.macroaxis.com 
BioMarin Pharmaceutical exotic insider transaction detected
Macroaxis News
Filed transaction by Biomarin Pharmaceutical I director. Unconventional Insider trading
over three weeks ago at www.macroaxis.com 
Payment of 2576 shares by Henry Fuchs of BioMarin Pharmaceutical subject to Rule 16b-3
Macroaxis News
Filed transaction by Biomarin Pharmaceutical I officer. Payment of exercise price or tax liability by delivering or withholding securities
over a month ago at http://macondaily.com 
American Century Companies Inc. Reduces Position in BioMarin Pharmaceutical
news
Macon DailyBioMarin Pharmaceutical Inc. CEO Jean Jacques Bienaime Sold 69743 Shares BangaloreWeeklyAt a Pivot Point Share Update on BioMarin Pharmaceutical Inc. and Markel Corporation Concordia ReviewFull coverage
over a month ago at http://globalexportlines.com 
Exercise or conversion by Bienaime Jean Jacques of 18750 shares of BioMarin Pharmaceutical subject to Rule 16b...
news
Filed transaction by Biomarin Pharmaceutical I director. Exercise or conversion of derivative security exempted pursuant to Rule 16b-3
over a month ago at http://www.thestocksnews.com 
BioMarin Pharmaceutical Inc. fluctuated 12.48 percent Monthly Good Performance
news
The Stocks News Full coverage
over two months ago at http://stocksmarketcap.com 
Exercise or conversion by Bienaime Jean Jacques of 1000 shares of BioMarin Pharmaceutical subject to Rule 16b-...
news
Filed transaction by Biomarin Pharmaceutical I director. Exercise or conversion of derivative security exempted pursuant to Rule 16b-3
over three months ago at http://www.dispatchtribunal.com 
Acquisition by Bienaime Jean Jacques of 45722 shares of BioMarin Pharmaceutical subject to Rule 16b-3
patch News
Filed transaction by Biomarin Pharmaceutical I director. Grant, award or other acquisition pursuant to Rule 16b-3

Did you try this?

Run Fundamentals Comparison Now
   

Fundamentals Comparison

Compare fundamentals across multiple equities to find investing opportunities
All  Next Launch Fundamentals Comparison

Profit Margin

Profit Margin Comparative Analysis
  Profit Margin 
      BioMarin Pharmaceutical Comparables 
BioMarin Pharmaceutical is currently under evaluation in profit margin category among related companies. Profit Margin measures overall efficiency of a company and shows its ability to withstand competition as well as defend against adverse conditions such as rising costs, falling prices, decline in sales or management distress. Profit margin tells investors how well the company executes on its overall pricing strategies as well as how effective the company in controlling its costs.

Peers

BioMarin Pharmaceutical Related Equities
BIO  1.04 %   
0%
27.0%
MRK  0.16 %   
4.0%
0%
LLY  0.24 %   
6.0%
0%
BMY  0.57 %   
15.0%
0%
ABT  0.63 %   
16.0%
0%
VRTX  0.67 %   
18.0%
0%
ENDP  1.48 %   
39.0%
0%
AGN  1.54 %   
41.0%
0%
MNK  3.71 %   
100.0%
0%
Check also BioMarin Pharmaceutical Hype Analysis, BioMarin Pharmaceutical Correlation and BioMarin Pharmaceutical Performance. Please also try Idea Breakdown module to analyze constituents of all macroaxis ideas. macroaxis investment ideas are predefined, sector-focused investing themes.